Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

Now a summer staple in Stratford, the World in a Weekend: International Puppet Festival is pushing itself to the limit by adding a fifth day of programming while welcoming performers from all corners ...

SpringWorks Therapeutics has established itself as a promising player in the U.S. Small & Mid Cap Biotechnology sector. The company’s primary focus has been on developing innovative therapies ...

SpringWorks maintains strong financial health with a current ratio of 4.33, indicating robust liquidity to support its commercialization efforts.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) has received a consensus recommendation of “Hold” from the eight brokerages that are covering the stock, MarketBeat.com reports ...

Merck KGaA will acquire SpringWorks Therapeutics, a US biopharmaceutical company focused on developing treatments for rare tumors. 1 According to a press release from SpringWorks, this will allow the ...

Merck KGaA has agreed to buy biotechnology company SpringWorks Therapeutics, announcing Monday a $3.9 billion deal after months of negotiations over an acquisition.

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union ...